Monopar Therapeutics Inc
MNPR
View Detailed Chart
68.770USD
-2.010-2.84%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
458.21MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-2.84%
5 Days
+0.20%
1 Month
-21.28%
6 Months
+104.67%
Year to Date
+212.59%
1 Year
+180.35%
View Detailed Chart
TradingKey Stock Score of Monopar Therapeutics Inc
Currency: USD Updated: 2025-12-26Key Insights
Monopar Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 117/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 111.77.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Monopar Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
13
analysts
Buy
Current Rating
111.769
Target Price
+46.24%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Monopar Therapeutics Inc Highlights
StrengthsRisks
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -17.37, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 3.34M shares, increasing 3.90% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 1.02K shares of this stock.
Monopar Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Monopar Therapeutics Inc Info
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Ticker SymbolMNPR
CompanyMonopar Therapeutics Inc
CEORobinson (Chandler D)
Websitehttps://www.monopartx.com/
FAQs
What is the current price of Monopar Therapeutics Inc (MNPR)?
The current price of Monopar Therapeutics Inc (MNPR) is 68.770.
What is the symbol of Monopar Therapeutics Inc?
The ticker symbol of Monopar Therapeutics Inc is MNPR.
What is the 52-week high of Monopar Therapeutics Inc?
The 52-week high of Monopar Therapeutics Inc is 105.000.
What is the 52-week low of Monopar Therapeutics Inc?
The 52-week low of Monopar Therapeutics Inc is 21.000.
What is the market capitalization of Monopar Therapeutics Inc?
The market capitalization of Monopar Therapeutics Inc is 458.21M.
What is the net income of Monopar Therapeutics Inc?
The net income of Monopar Therapeutics Inc is -15.59M.
Is Monopar Therapeutics Inc (MNPR) currently rated as Buy, Hold, or Sell?
According to analysts, Monopar Therapeutics Inc (MNPR) has an overall rating of Buy, with a price target of 111.769.
What is the Earnings Per Share (EPS TTM) of Monopar Therapeutics Inc (MNPR)?
The Earnings Per Share (EPS TTM) of Monopar Therapeutics Inc (MNPR) is -3.959.
Related Instruments
+0.05%
-0.07%
+0.08%
+0.49%
+0.23%
+0.38%
-0.31%
-0.30%
-0.77%
+0.30%
+0.23%
-0.02%
-0.07%
+0.24%
+0.26%
+0.30%
+0.16%
0.00%
+0.58%
-0.02%Popular Symbols
